Eikon Therapeutics presents clinical data for PARP1 and WRN helicase programs at ESMO 2026

Eikon Therapeutics presented clinical data at the 2026 ESMO Congress in Madrid, including updated efficacy results for EIK1003, a selective non-brain-penetrant PARP1 inhibitor, in platinum-resistant ovarian and breast cancer cohorts, and initial data for WRN helicase inhibitors EIK1004 and EIK1005.

Detected & updated continuously · Source: Nebula